Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: Report of two cases

Hepatitis Monthly

Volumn 13, Issue 9, 2013, Pages

  Marinelli, Sara ^a   Granito, Alessandro ^a   Piscaglia, Fabio ^a   Renzulli, Matteo ^a   Stagni, Angela ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Capecitabine; Hepatocellular carcinoma; Sorafenib

Indexed keywords

CAPECITABINE; EMOLLIENT AGENT; SORAFENIB; UREA;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; METRONOMIC DRUG ADMINISTRATION; TREATMENT RESPONSE; TUMOR NECROSIS; VASCULARIZATION;

EID: 84884676479     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.11721     Document Type: Article

References (14)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36.
3. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10(1):25-34.
4. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410-26.
5. Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology. 2013;57(3):1068-77.
6. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
7. Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol. 2010;17(1):59-63.
8. Emmenegger U, Kerbel RS. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie. 2007;30(12):606-8.
9. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-36.
10. Brandi G, de Rosa F, Bolondi L, Agostini V, Di Girolamo S, Nobili E, et al. Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori. 2010;96(6):1028-30.
11. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101(3):578-86.
12. Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010;17(12):3137-44.
13. Ballardini P, Marri I, Margutti G, Aliberti C, Benea G, Manfredini R. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma. Tumori. 2010;96(5):768-70.
14. Maraveyas A, Lam T, Hetherington JW, Greenman J. Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer. 2005;92(8):1588-90.